Evercore ISI removes IBM stock from tactical list after earnings By Investing.com

IBM beat March-quarter expectations with revenue of $15.9 billion versus $15.6 billion consensus and non-GAAP EPS of $1.91 versus $1.81 expected, while maintaining guidance. Software revenue rose 11.3% year over year, Infrastructure climbed 15.2%, and free cash flow totaled $2.2 billion, though the stock remains down 22% year to date and near its 52-week low. Evercore ISI kept an Outperform rating and $310 target, and IBM continued to emphasize AI and quantum initiatives through partnerships and the launch of IBM Bob.

Analysis

IBM’s setup is less about this quarter and more about whether the market is underpricing the durability of its cash flow while extrapolating disruption risk too aggressively into the legacy software stack. The AI/quantum narrative is acting as a valuation reset mechanism: if management can keep software growing mid-single digits and preserve high-50s gross margin, the multiple can grind higher even without a step-up in guidance. The key second-order effect is that IBM becomes a relative safe harbor for enterprise buyers looking for governed AI rather than frontier-model experimentation, which can quietly extend its relevance in regulated industries.

The broader implication for competitors is that the AI spend that headlines usually attribute to hyperscalers may increasingly be captured by orchestration, security, and workflow layers rather than model providers alone. That is constructive for IBM’s services and software mix, but also highlights pressure on pure-play software names whose value proposition depends on low-friction automation. If IBM’s AI tooling gains traction inside enterprise procurement processes, it could slow churn in large installed bases across consulting-adjacent vendors and reduce the odds of a near-term secular re-rating in the software group.

The market’s biggest blind spot is likely time horizon: the bear case is a multiple compression story over the next 1-2 quarters, but the bull case is a steady compounding story over 12-24 months. Near term, the stock still needs proof that AI products are additive rather than just narrative support; any softening in consulting or guidance reiteration will cap upside quickly. Longer term, the combination of recurring cash generation and dividend support makes IBM more sensitive to rates and risk appetite than to one quarter of execution, which helps explain why the drawdown may be overdone relative to fundamentals.

Key Decisions for Investors

• Long IBM vs short a basket of high-multiple enterprise software names on a 3-6 month horizon; the trade is a relative valuation rotation if IBM’s cash flow remains stable and AI spend stays governed rather than speculative.
• Buy IBM on further weakness near the 52-week low with a 6-12 month hold; upside is a re-rating toward its historical premium if investor concern over AI disruption proves overstated, while downside is supported by dividend/FCF characteristics.
• Sell covered calls against existing IBM longs over the next 1-2 quarters; implied upside is likely capped until management demonstrates that AI products are materially contributing to backlog or margin expansion.
• Pair IBM long / short a consulting-heavy or legacy software peer that is more exposed to AI displacement risk; thesis duration 1-2 quarters, with best payoff if enterprise customers delay discretionary spend but keep mission-critical IBM contracts intact.
• Avoid chasing the move in IBM after the earnings beat; wait for a pullback or for a catalyst confirming AI monetization, since the current setup is more valuation repair than imminent growth acceleration.